| Revision as of 14:50, 10 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 466156572 of page Urtoxazumab for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 23:49, 5 April 2023 edit Entranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,035 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper |
| Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 450332165 |
|
| verifiedrevid = 470620672 |
|
| image = |
|
| image = |
|
|
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = zu/o |
|
| source = zu/o |
|
| target = '']'' ] II B subunit |
|
| target = '']'' ] II B subunit |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
| Line 22: |
Line 21: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
| Line 29: |
Line 27: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
⚫ |
| CAS_number_Ref = {{cascite|changed|??}} |
| ⚫ |
<!--Identifiers--> |
|
|
⚫ |
| CAS_number = 502496-16-4 |
| ⚫ |
| CAS_number_Ref = {{cascite|correct|??}} |
|
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
| ⚫ |
| CAS_number = <!-- blanked - oldvalue: 502496-16-4 --> |
|
|
|
| UNII = 232D35B3NT |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
| Line 39: |
Line 38: |
|
| DrugBank = |
|
| DrugBank = |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
⚫ |
| C=6414 | H=9934 | N=1718 | O=2010 | S=40 |
| ⚫ |
<!--Chemical data--> |
|
| ⚫ |
| C=6414 | H=9934 | N=1718 | O=2010 | S=40 |
|
|
| molecular_weight = 144.6 ] |
|
|
}} |
|
}} |
|
|
|
|
|
'''Urtoxazumab''' is a ] against ] caused by '']'', serotype ]. The drug is designed to bind to a ] of this bacterium, so that it can be more easily broken down and eliminated from the body.<ref>{{cite web | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN.pdf | title = International Nonproprietary Names for Pharmaceutical Substances (INN) | publisher = World Health Organization }}</ref><ref>{{cite journal | vauthors = López EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S | display-authors = 6 | title = Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli | journal = Antimicrobial Agents and Chemotherapy | volume = 54 | issue = 1 | pages = 239–43 | date = January 2010 | pmid = 19822704 | pmc = 2798559 | doi = 10.1128/AAC.00343-09 }}</ref> |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
{{Monoclonals for infectious disease and toxins}} |
|
|
|
|
|
] |
|
|
] |
|
|
|
|
|
{{antiinfective-drug-stub}} |
|
|
{{monoclonal-antibody-stub}} |